Results 261 to 270 of about 54,977 (304)
Some of the next articles are maybe not open access.
Toward Ablative SBRT for Nonmetastatic PDAC
Cancer Discovery, 2023Abstract Combining a superoxide dismutase mimetic, avasopasem manganese, with stereotactic body radiation therapy may enable safe delivery of higher than standard radiation doses for patients with nonmetastatic, inoperable pancreatic adenocarcinoma.
openaire +2 more sources
A hypoxic ride for neutrophils in PDAC
Gut, 2022Daniela Cerezo-Wallis, Andrés Hidalgo
openaire +2 more sources
DNA sequencing data of 41 paired PDAC patients and RNA-seq encing data of 41 normal PDAC ...
openaire +1 more source
openaire +1 more source
KRAS degradation averts PDAC chemoresistance
Nature CancerEffectively targeting deregulated KRAS signaling remains an unmet clinical need, as current approaches commonly lead to the development of chemoresistance in clinical settings. ADAM9-mediated lysosomal KRAS degradation is now shown to counteract PDAC chemoresistance independently of mutational status.
Laura Leonhardt, Matthias Hebrok
openaire +3 more sources
Epigenomic Changes Prime PDAC Metastasis
Cancer Discovery, 2017Abstract Widespread chromatin modifications and DNA methylation could be responsible for inducing the spread of pancreatic ductal adenocarcinoma cells to distant sites, according to recent research. The findings also implicate glucose metabolism as a driver of metastasis.
openaire +2 more sources
Personalized Models of Human PDAC
2020Pancreatic cancer is one of the most aggressive malignancies with large inter- and intratumoural heterogeneity and an extremely poor prognosis. Uniform treatments adapted to disease states, but ignoring the individual cancer biology, are still the standard of care. Yet, response to therapy varies substantially among pancreatic cancer patients, and most
Hanna Heikenwälder, Susanne Roth
openaire +1 more source
hENT1 as a Predictive Biomarker in PDAC—Response
Clinical Cancer Research, 2023Sheron Perera +7 more
openaire +3 more sources